SCHEMBL21473788

SCHEMBL21473788

COc1cc(CC(O)C(C)C)c(CNC(=O)OC(C)(C)C)cn1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 2/20 0.38
KCNA5 P22460 1/20 0.36
L3MBTL1 Q9Y468 3/20 0.36
GFER P55789 1/20 0.36
HSD17B10 Q99714 1/20 0.36
AAK1 Q2M2I8 1/20 0.36
KDM4E B2RXH2 1/20 0.35
LMNA P02545 1/20 0.35
ABCB1 P08183 1/20 0.35
KDM4A O75164 1/20 0.34
MTNR1A P48039 1/20 0.34
MTNR1B P49286 1/20 0.34
DYRK1A Q13627 1/20 0.34
MEN1 O00255 1/20 0.34
PABPC1 P11940 1/20 0.34
KMT2A Q03164 1/20 0.34
MAPT P10636 2/20 0.34
RECQL P46063 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
PDPK1 O15530 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30463073 1.00 TRPV1 (0.38) TRPV1KCNA5L3MBTL1GFERHSD17B10
SCHEMBL21327577 0.86 KMT2A (0.40) KDM4EMTNR1AMTNR1BMEN1PABPC1
SCHEMBL21327200 0.83 TRPV1 (0.35) TRPV1KCNA5L3MBTL1GFERHSD17B10
SCHEMBL29050608 0.83 TRPV1 (0.35) TRPV1KCNA5L3MBTL1GFERHSD17B10
SCHEMBL30463069 0.83 TRPV1 (0.35) TRPV1KCNA5L3MBTL1GFERHSD17B10
SCHEMBL21327092 0.82 TRPV1 (0.38) TRPV1KCNA5L3MBTL1GFERHSD17B10
SCHEMBL21473817 0.80 NNMT (0.43) TRPV1L3MBTL1GFERHSD17B10AAK1
SCHEMBL10268457 0.79 MTNR1A (0.39) TRPV1L3MBTL1GFERHSD17B10KDM4E
SCHEMBL13881875 0.79 STK17B (0.46) TRPV1L3MBTL1GFERHSD17B10KDM4A
SCHEMBL29050610 0.76 L3MBTL1 (0.34) TRPV1KCNA5L3MBTL1GFERHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116751200-A Tricyclic compounds containing substituted pyridones and methods of using the same 爱彼特生物制药公司 2023-09-15 CN disclosed
CN-110114071-B Tricyclic compounds containing substituted pyridones and methods of using the same 爱彼特生物制药公司 2023-07-04 CN disclosed
EP-3534903-B1 SUBSTITUTED PYRIDINONE-CONTAINING TRICYCLIC COMPOUNDS, AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (CA) 2022-08-03 EP disclosed
US-11013726-B2 Substituted pyridinone-containing trycyclic compounds, and methods using same ARBUTUS BIOPHARMA CORPORATION (CA) 2021-05-25 US disclosed
US-10821103-B2 Substituted pyridinone-containing trycyclic compounds, and methods using same ARBUTUS BIOPHARMA CORPORATION (CA) 2020-11-03 US disclosed
US-20200261432-A1 SUBSTITUTED PYRIDINONE-CONTAINING TRYCYCLIC COMPOUNDS, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2020-08-20 US disclosed
US-20190314347-A1 SUBSTITUTED PYRIDINONE-CONTAINING TRYCYCLIC COMPOUNDS, AND METHODS USING SAME ARBUTUS BIOPHARMA, INC. 2019-10-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200261432-A1 SUBSTITUTED PYRIDINONE-CONTAINING TRYCYCLIC COMPOUNDS, AND METHODS USING SAME HAVCR2, HCCS, TYMP TRPV1 2251/4885KCNA5 2763/4885L3MBTL1 4218/4885
US-20190314347-A1 SUBSTITUTED PYRIDINONE-CONTAINING TRYCYCLIC COMPOUNDS, AND METHODS USING SAME HAVCR2, HCCS, TYMP TRPV1 2251/4885KCNA5 2763/4885L3MBTL1 4218/4885
US-11013726-B2 Substituted pyridinone-containing trycyclic compounds, and methods using same HAVCR2, HCCS, TYMP TRPV1 2251/4885KCNA5 2763/4885L3MBTL1 4218/4885
US-10821103-B2 Substituted pyridinone-containing trycyclic compounds, and methods using same HAVCR2, HCCS, TYMP TRPV1 2251/4885KCNA5 2763/4885L3MBTL1 4218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.